ClinicalTrials.gg
Status unknownNCT03324841Updated Jan 27, 2020

POA Prospective Repository

An observational study in Solid Tumor, Adult and Oncology, sponsored by Caris Science, Inc.. Status unknown at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-27.

Sponsored by Caris Science, Inc. · Observational

How we know

The sponsor has not verified this record recently (last verified Jan 2020), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Study summary

This repository is a multi-center, outcomes study designed to collect data on the demographics, presentation, diagnosis, treatment, cost of associated care, quality of life, and outcomes of subjects utilizing Caris Molecular Intelligence® (CMI) Services for the treatment of cancer.

Read the detailed description

This repository is a multi-center, outcomes study designed to collect data on the demographics, presentation, diagnosis, treatment, cost of associated care, quality of life, and outcomes of subjects utilizing Caris Molecular Intelligence® (CMI) Services for the treatment of cancer. Prior to enrolling a subject, the subject's physician will have made the independent decision whether or not to utilize the drug associations provided by CMI and made clinical treatment choices as appropriate. Thus, data captured and reported provides a "real world" perspective on diagnosis, treatment, cost, and outcomes.

Prospective data will be obtained only from consented patients or patients who have died or have been lost to follow-up. Lost to follow-up is defined as a subject who has not returned for continued care or evaluation (e.g., disability, relocation or unresponsiveness). Site coordinators are required attempt to contact the subject 3 times before deeming them lost to follow up. Data collection and the protection of privacy are discussed in the Methods section below.

In addition to treatment and response data, initial diagnosis and staging results will be recorded as well as any recurrence information. As the investigators are capturing the subject's cancer treatment as a whole, results from pertinent cancer-related tests performed by outside entities for eligible subjects will need to be collected by the site coordinator and maintained at the site accordingly for reporting and monitoring purposes.

02

Conditions studied

  • Solid Tumor, Adult
  • Oncology

Browse trials for

Keywords

  • Molecular Profiling
  • Biomarker Analysis
  • Next Generation Sequencing
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Caris Science, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Subjects who received Caris MI Profiling at one of the Precision Oncology Alliance (POA) sites

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject's age must be greater than or equal to 18 years and must have received CMI testing

Exclusion criteria

Exclusion Criteria:

  • Due to the complexity of state and federal requirements governing the participation of prisoners in research, prisoners-patients shall not be approached for participation.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • MI Profiling

    Subjects must have undergone Caris MI Profiling in order to be eligible for the study. No required intervention is dictated by the protocol.

    Diagnostic Test: Caris MI Profiling

Interventions

  • Diagnostic testCaris MI Profiling

    Customized comprehensive biomarker testing

06

What researchers measure

Primary outcomes

  1. Effecting Change

    Effecting change in disease treatment processes by advancing precision medicine and improving care for cancer through acquiring and sharing valuable molecular tumor profiling information and clinical outcomes in a collaborative, secure environment.

    Time frame: within 5 years

  2. Performing retrospective research

    Performing retrospective research including clinical presentation, treatment and outcomes. This eligible cohort includes select subjects who have already undergone Caris Molecular Intelligence® evaluation for diagnosis and/or treatment management.

    Time frame: within 5 years

  3. Evaluate the frequency of specific clinical events

    Evaluate the frequency of specific clinical events in relation to risk factors, diagnosis and treatments provided via the collection of outcomes data through automated data capture systems provided by a third-party data entity and manually-entered data when needed.

    Time frame: within 5 years

  4. Provide information access that is vital to research collaborators

    Provide information access that is vital to research collaborators, including potential researchers from pharmaceutical companies, governmental agencies, academia, healthcare providers, and payors, with catalogued subject outcome data for the use of drug development discoveries, clinically relevant research trials, publications and posters, the implementation of future healthcare policies, characterization of trends in practice patterns and their relation to subject outcomes and the economic impact of differing evaluation, treatment, and management paradigms.

    Time frame: within 5 years

  5. Cultivate a repository for assay development

    Cultivate a repository for assay development and validation of emerging technologies to enhance clinical cancer care.

    Time frame: within 5 years

07

Study locations

11 sites
  • HonorHealth
    Scottsdale, Arizona 85258, United States
  • University of Arizona
    Tucson, Arizona 85719, United States
  • St. Joseph Heritage Healthcare
    Irvine, California 92612, United States
  • John Wayne Cancer Institute
    Santa Monica, California 90404, United States
  • MedStar Health Research Institute, Inc.
    Washington, District of Columbia 20007, United States
  • AdventHealth Orlando Cancer Institute
    Orlando, Florida 32803, United States
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • University of Cincinnati Health, LLC
    Cincinnati, Ohio 45219, United States
  • The Institute for Cancer Research dba The Research Institute of Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • The West Clinic
    Germantown, Tennessee 38138, United States
  • The University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2017 (actual). Primary completion is estimated for Jan 2023, 66 months after the start.

Of 148 industry-sponsored observational studies under Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 102. This study's planned 66 months is above that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2017
First posted
Oct 30, 2017
StartActual
Jun 7, 2017
Primary completionEst.
Jan 1, 2023
CompletionEst.
Jan 1, 2023
Last update
Jan 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03324841
Lead sponsor
Caris Science, Inc.
Responsible party
Sponsor
First posted
Oct 30, 2017
Start date
Jun 7, 2017
Primary completion
Jan 1, 2023 (estimated)
Completion
Jan 1, 2023 (estimated)
Last update
Jan 27, 2020

Study contacts

W. Michael Korn, MD
study director · Caris Life Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion